Aldeyra Therapeutics Inc
Fechado
1.53 6.99
Visão Geral
Variação de preço das ações
24h
Mín
1.43
Máximo
1.56
Rendimento | -8.9B -8.9B |
|---|---|
EPS | -0.16 |
Funcionários | 7 |
EBITDA | -2.5M -5.5M |
Próximos Ganhos | 3 de nov. de 2026 |
|---|
Capitalização de Mercado | -1.2M 91M |
|---|---|
Abertura anterior | -5.46 |
Fecho anterior | 1.53 |
Aldeyra Therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Aldeyra Therapeutics Inc Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.